Kingy AI
Subscribe, 2.1M subscribersWork with Kingy

Breakthrough Tracker record

FDA approves the first treatment for ataxia in ataxia-telangiectasia

FDA approved levacetylleucine for ataxia in people with ataxia-telangiectasia weighing at least 15 kilograms. In a 73-participant randomized crossover trial, 12 weeks of treatment improved SARA scores by an estimated 1.88 points versus placebo.

← Back to the filtered Breakthrough Tracker

Stable ID
medicine-levacetylleucine-ataxia-telangiectasia-fda-2026
Revision
medicine-levacetylleucine-ataxia-telangiectasia-fda-2026.v1
Field
Medicine · Rare neurogenetic disease and symptomatic therapy
Evidence
Tier 1 · Peer reviewed: Yes
Record state
Current · FDA approved
Last checked

AI role

No substantive AI role was disclosed in the regulator decision or inspected trial records.

Record details

Problem or result
Symptomatic treatment of ataxia in ataxia-telangiectasia
Authors
Kyriakos Martakis, Tatiana Bremova-Ertl, Clare Bolton and the multinational phase 3 investigators
Institutions
Ten multinational trial hospitals; University of Cologne; Bern; UCLA; Massachusetts General Hospital; UTHealth Houston; IntraBio
Result date
FDA approval September 18, 2026

Why it matters

Ataxia-telangiectasia causes progressive childhood-onset coordination loss, immune defects and cancer susceptibility. This is the first FDA-approved treatment for its disabling ataxia.

Limits

The rare-disease trial was small, sponsor-funded and limited to 12 weeks per period. The approval concerns symptomatic improvement; long-term neuroprotection or disease modification is unproven.

Sources

  1. Regulator: FDA approval announcement for levacetylleucine
  2. Regulator: FDA orphan-drug approval record
  3. Primary: Peer-reviewed phase 3 PubMed record
  4. Specialist context: National Ataxia Foundation evidence summary

Correction and revision history

  1. 2026-10-02 — Added after primary-source, scope, status, AI-role and limitation review.

Machine-readable: JSON v1 · CSV v1 · Schema v1

This individual record remains noindex until a story-specific featured image passes Kingy’s rendered-pixel visual review. The source-linked tracker hub remains the public index.